Effect gingivitis on anti-mullierian hormone in females with polycystic ovary syndrome
Paper Details
Effect gingivitis on anti-mullierian hormone in females with polycystic ovary syndrome
Abstract
Polycystic ovary syndrome is a mutual disease affected about 4% to 12% women in propagative age. Anti-mullerian hormone (AMH) is a glycoprotein, a member of the transforming growth factor-b family. It plays a master role in cell growth and differentiation. Polycystic ovary syndrome (PCOS) is a hormonal disorder of women that not only is the leading cause of infertility but also shows a reciprocal link with oral health. Gingivitis was inflammed disorders it has linked with altered vascular reaction, high levels of adhesion molecules and elevated expression of local and systemic inflammatory cytokines and adipokines like tumor necrosis factor- alpha and transforming growth factor-beta. Increased gingival inflammation is related with increased synthesis of steroid hormone. Therefore, The aims of the study to examine the effect gingivitis and PCOS on levels of AMH and study the relation between PCOS and gingivitis in women and if AMH is useful marker in diagnosis of gingivitis and PCOS. A total 84 women of age group between (20 – 28) years were included in this study. Twenty one female who had PCOS and (21) female with periodontal diseases (gingivitis), (21) female who possess both PCOS and gingivitis and (22) healthy females with regular menstrual cycle who presented sequentially and prospectively to the Department of Endocrinology of Al-Rumadi teaching hospital/ Al-Anbar/Iraq. High significant elevation in saliva AMH in PCOS with gingivitis group than in PCOS, gingivitis and control group p<0.05. High concentration of AMH in PCOS with gingivitis make suggested all Physicians must refer PCOS patients to oral health clinic providers for a comprehensive oral evaluation and treatment.
Akcali A, Bostanci N, Özçaka Ö, Öztürk-Ceyhan B, Gümü SP, Buduneli N. 2014. Association between polycystic ovarys yndrome, oral microbiota and systemic antibody responses, PLo SONE 9(9), e108074. https://doi.org/10.1371/journal.pone.0108074
Annemarie DV, Joop SEL, Frank HDJ, Axel PNT, Bart CJMF. 2002. Antimüllerian hormone serum levels: a putative marker for ovarian aging, Fertility and Sterility, 77(2), 357–62. https://doi.org/10.1016/S0015-0282(01)02993-4
Annemarie DV, Joop SEL, Frank HDJ, Axel PNT, Bart CJMF. 2002. Regulation of ovarian function: the role of anti-Müllerian hormone, (Cambridge, England), 124(5), 601-609. https://doi.org/10.1530/rep.0.1240601
Bachanek M, Abdalla N, Cendrowski K, Sawicki W. 2015. Value of ultrasonography in the diagnosis of polycystic ovary syndrome—literature review. Journal of Ultrasonogrology, 15, 410–422.
Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T. 2006. Inflammatory and endothelial markers in women with polycystic ovary syndrome, European Journal of Clinics Invest 36, 691–697.
Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG. 1999. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile. Journal of Clinical Endocrinology and Metabolism 84, 4006–4011.
Dokras A. 2016. Cardiovascular disease risk in women with PCOS, Steroids 78, 773–776.
Dursun E, Akalin FA, Guncu GN, Cinar N, Aksoy DY, Tozum TF. 2011. Periodontal disease in polycystic ovary syndrome, Fertility and Sterility 95, 320–323.
Ebejer K, Calleja-Agius J. 2013. The role of cytokines in polycystic ovarian syndrome, Gynecological Endocrinology 29, 536–540.
Evangelista O, McLaughlin MA. 2009. Review of cardiovascular risk factors in women. Gender Medicine 6(1), 17–36.
Genco RJ, Grossi SG, Ho A, Nishimura F, Murayama Y. 2005. A proposed model linking inflammation to obesity, diabetes, and periodontal infections, Journal of Periodontology 76(11), 2075–2084.
Gnoth C, Schuring AN, Friol K, Tigges J, Mallmann P, Godehardt E. 2008. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Human Reproduction, 23, 1359–1365.
Hsu MI. 2013. Changes in the PCOS phenotype with age, Steroids 78, 761–766.
Javed F, Kellesarian SV, Al-Kheraif AA, Ranna V, Qadri T, Yunker M. 2016. Effect of Nd:YAG laser-assisted non-surgical periodontal therapy on clinical periodontal and serum biomarkers in patients with and without coronary artery disease: a short-term pilot study. Lasers Surgery and Medicine 48, 929–935.
Katz J, Flugelman MY, Goldberg A, Heft M. 2012. Association between periodontal pockets and elevated cholesterol and low density lipoprotein cholesterol levels. Journal of Periodontology 73, 494–500.
Kim J, Amar S. 2006. Periodontal disease and systemic conditions: A bidirectional relationship, Odontology 94(1), 10–21.
Korhonen S, Hippeläinen M, Vanhala M, Heinonen S, Niskanen L. 2003. The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: A controlled community-based study. Fertility and Sterility 79, 1327–1334.
Kubota T. 2013. Update in polycystic ovary syndrome: new criteria of diagnosis and treatment in Japan. Reproductive Medicine and Biology 12, 71–77.
Lim SS, Norman RJ, Davies MJ, Moran LJ. 2013. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obesity Review 14, 95–109.
Loe H, Silness J. 1963. Periodontal disease in pregnancy. I Prevalence and severity, Acta Odontologica Scandinavic 21, 533-551.
March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. 2010. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction 25, 544–551.
Marchetti E, Monaco A, Procaccini L, Mummolo S, Gatto R, Tetè S. 2012. Periodontal disease: The influence of metabolic syndrome, Nutrition Metabolism 9, 88. https://doi.org/10.1186/1743-7075-9-88
Molly MQ, Chia-Ning K, Asima KA, Daniel JH, Nanette S, Esther E, Richard SL, Marelle IC, Heather GH. 2017. Age-stratified thresholds of anti-Müllerian hormone improve prediction of polycystic oveary syndrome over a population-based threshold. the NIH/NICHD Reproductive Medicine Network Clinical Endocrinology 87(6), 733-740.
Moran LJ, Misso ML, Wild RA, Norman RJ. 2010. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis, Hum Reproduction Update 16, 347–363.
Nair SD, Varma S, Suragimath G, Zope S, Kale V, Abbayya K. 2017. PREVALENCE OF Periodontal DiseasE in Women With Polycystic Ovary Syndrome- A Comparative Descriptive Study 6(65), 4733-4736. https://doi.org/10.14260/Jemds/2017/1025
Ozcaka O, Buduneli N, Ceyhan BO, Akcali A, Hannah V, Nile C. 2013. Is interleukin-17 involved in the interaction between polycystic ovary syndrome and gingival inflammation?, Journal of Periodontology 84, 1827–1837.
Ozcaka O, Ceyhan BO, Akcali A, Bicakci N, Lappin DF, Buduneli N. 2012. Is there an interaction between polycystic ovary syndrome and gingival inflammation?, Journal of Periodontology, 83, 1529–1537.
Pankhurst MW. 2017. A putative role for anti-mullerian hormone (AMH) in optimizing ovarian reserve expenditure. Journal of Endocrinology, 233(1), R1-R13.
Porwal S, Tewari S, Sharma RK, Singhal SR, Narula SC. 2014. Periodontal status and high-sensitivity C-reactive protein levels in polycystic ovary syndrome with and without medical treatment. Journal of Periodontology 85, 1380–1389.
Rahiminejad ME, Moaddab A, Rabiee R, Esna-Ashari F, Borzoui Sh, Hosseini SM. 2014. The relationship between clinico biochemichal markers and depression in patient with polycystic ovary syndrome. Iranian Journal of Reproductive Medicine 12, 811–816.
Rahiminejad ME, Moaddab A, Zaryoun H, Rabiee S, Moaddab A, Khodadoustan A. 2015. Comparison of prevalence of periodontal disease in women with polycystic ovary syndrome and healthy controls, Dental Research Journal, 12, 507–512.
Reeves AF, Rees JM, Schiff M, Hujoel P. 2006. Total body weight and waist circumference associated with chronic periodontitis among adolescents in the United States. Archives of Pediatrics and Adolescent Medicine 160, 894–899.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 81, 19–25.
Sam S, Dunaif A. 2003. Polycystic ovary syndrome: Syndrome XX? Trends in Endocrinology and Metabolism, 14, 365–370.
Visser JA, de-Jong FH, Laven JS, Themmen AP. 2006. Anti-Müllerian hormone: a new marker for ovarian function, Reproduction, 131, 1–9. https://doi.org/10.1530/rep.1.00529
Wild RA. 2012. Dyslipidemia in PCOS, Steroids 77, 295–299.
World Health and Organization. 2008. Waist circumference and waist–hip ratio Report of a WHO expert consultation, Geneva.
Yildiz BO, Bolour S, Woods K, Moore A, Azziz R. 2010. Visually scoring hirsutism. Human Reproductive Update 16, 51–64.
Shaimaa Sabte Mutlak, Noora Abd Awad, Elham Hazeim Abdulkareem, 2018. Effect gingivitis on anti-mullierian hormone in females with polycystic ovary syndrome. Int. J. Biosci., 13(3), 165-172.
Copyright © 2018 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.